In partnership with
TESTING LSD FOR ANXIETY TREATMENT
Researchers Tested LSD As A Treatment For Anxiety
Legal Clinical Research With LSD Almost Stopped After The 1970s
Licensed Trials Have Been Running Again For Years
One Of Them Treated Adults With Generalised Anxiety Disorder
Each Person Swallowed A Single Measured Dose
Some Of Them Were Given A Placebo Instead
Trained Raters Scored Their Anxiety Weeks Afterwards
Whether One Dose Is Enough Is Still Being Tested
THIS NEWSLETTER IS FOR INFORMATIONAL PURPOSES ONLY. NOTHING IN THIS CONTENT CONSTITUTES MEDICAL, PSYCHOLOGICAL, OR PROFESSIONAL ADVICE. ALWAYS CONSULT A QUALIFIED HEALTHCARE PROFESSIONAL BEFORE MAKING ANY HEALTH RELATED DECISIONS.
A Quick Shoutout To Our Sponsor: HUBSPOT
Here's What They Have For You 🔸
👇🏻
No follow-up questions required
Every sales leader knows the feeling. You walk into a pipeline review with a number you believe in, and twenty minutes later, you're defending every line item to a CEO who just wants to know what's actually going to close.
HubSpot Sales Hub ends that conversation. Every deal, every rep's activity, and every buyer signal are all in one place and updated automatically. So your forecast is built on what's actually happening. And when you present that number, you can stand behind it.
OKAY BACK FROM THE CLINIC 🩺
👇🏻
WHAT THE TRIAL DID 🧫
The Compound Tested Was Lysergide D Tartrate
Its Development Code Is MM120
The Trial Was Phase 2b
It Was Multicentre And Randomised
The Design Was Double Blind And Placebo Controlled
198 Adults Were Randomised Into It
194 Of Them Entered The Full Analysis Set
Every Participant Had Moderate To Severe Generalised Anxiety Disorder
Each One Received A Single Dose
Four Dose Levels Were Tested Against Placebo
The Lowest Was 25 Micrograms And The Highest Was 200 Micrograms
Two Middle Levels Of 50 And 100 Micrograms Completed The Set
A Second Dose Was Not Part Of The Design
Psychotherapy Was Not Part Of The Treatment
Dosing Session Monitors Were Prohibited From Providing It
Participants Already In Therapy Could Continue
Its Design Also Fixed What Would Be Measured
The Primary Endpoint Was A Dose Response Relationship
Researchers Assessed It With A Modelling Method
The Measure Was Change In A Hamilton Anxiety Score
That Change Was Read At Four Weeks
The Design Named That Timepoint In Advance
A Quick Shoutout To Our Sponsor: MINDSTREAM
Here's What They Have For You
👇🏻
Master Claude AI (Free Guide)
The professionals pulling ahead aren't working more. They're using Claude.
Our free guide will show you how to:
Configure Claude to be the perfect assistant
Master AI-powered content creation
Transform complex data into actionable strategies
Harness Claude’s full potential
Transform your workflow with AI and stay ahead of the curve with this comprehensive guide to using Claude at work.
WHAT IT FOUND 📉
Two Dose Groups Separated From Placebo At Four Weeks
The 100 Microgram Group Was One Of Them
Its Least Squares Mean Difference Was Minus 5.0 Points
The Confidence Interval Ran From Minus 9.6 To Minus 0.4
That Interval Does Not Cross Zero
The Result Was Therefore Statistically Significant
Its Nearer Bound Is Only Four Tenths Of A Point
A Wide Interval Leaves The Size Of The Effect Uncertain
The 200 Microgram Group Did Better On Both Counts
That Difference Was Minus 6.0 Points
Its Interval Ran From Minus 9.8 To Minus 2.0
Response Meant An Anxiety Score Cut By Half
It Was Measured Again At Twelve Weeks
65.0% Of The 100 Microgram Group Reached It
62.5% Of The 200 Microgram Group Did Too
30.8% Of The Placebo Group Reached It As Well
Remission Rates Were 47.5% And 45.0% Against 20.5%
Those Run In The Same Order As The Response Figures
Placebo Response Was Not Small In Either Measure
The Same Trial Recorded Its Adverse Events
Visual Perceptual Changes Were The Most Common Adverse Event
They Affected 92.5% Of The 100 Microgram Group
Nausea Affected 40% And Headache 35%
Most Of Those Resolved By The End Of The Dosing Session
The Authors List Their Own Limitations
Perceptible Drug Effects Could Unblind A Participant
Interpersonal Interaction Could Confound The Result
Dropout Was Slightly Higher Than In Similar Studies
The Rate Was Similar Across Groups
A Quick Shoutout To Our Sponsor: HUBSPOT
Here's What They Have For You 🟠
👇🏻
2 minutes. Your URL. A customer profile worth using.
Most founders can describe their product. They can't describe their customer. Not in a way that actually changes how they sell.
HubSpot for Startups built a free tool to fix that. Paste in your URL, answer a few quick questions, and it generates a structured profile of your best-fit customer. Firmographics, buying triggers, the works.
Takes 2 minutes. No spreadsheet required.
WHAT A DESIGNATION IS NOT 🚦
The Food And Drug Administration Granted Breakthrough Designation
That Happened On 7 March 2024
Generalised Anxiety Disorder Was The Named Indication
Such A Designation Is Meant To Expedite Development And Review
It Is Not An Approval
Two Phase 3 Studies Followed
The First Is Called Voyage
Voyage Enrolled 214 Adults In The United States
The Second Is Called Panorama
Panorama Runs In The United States And Europe
It Aims To Enrol About 250 Participants
Panorama Adds A 50 Microgram Group
Both Measure Anxiety Scores At Twelve Weeks
Voyage Reported Its Result On 12 August 2026
Its Participants Took A Fast Dissolve Tablet Of LSD
Anxiety Scores Fell 11.6 Points On A Single 100 Microgram Dose
The Placebo Group Fell 6.2 Points
That Difference Of 5.4 Points Was Statistically Significant
A Different Compound Reached The Approval Stage First
MDMA Was Submitted For Post Traumatic Stress Disorder
A Complete Response Letter Arrived In August 2024
The Therapy Was Not Approved
That Compound Is Not Lysergic Acid Diethylamide
An Application Can Still Be Declined
Topline Data From Panorama Is Expected In September 2026
